Astellas is one of the top 20 pharmaceutical companies in the world, employing 16,000 people globally. As a young and forward-thinking company, Astellas is dedicated to improving the lives of people around the world through the introduction of innovative and reliable pharmaceutical products.
Since the merger of Yamanouchi and Fujisawa, Astellas continues to remain committed to developing first-in-class and best-in-class products in key therapeutic areas by combining outstanding R&D with marketing capabilities and continuing growth in the world pharmaceutical market.
In October 2006, Astellas launched its management vision, VISION 2015, with the aim of becoming a Global Category Leader (GCL) in several therapeutic categories in which high unmet medical needs exist and an exceptional degree of expertise is required. Integral to this vision is Changing tomorrow, a wide-reaching campaign launched in 2008 that aims to express the company's potential for creating a better tomorrow for all its stakeholders.
With global sales reaching ¥953.9 billion* against an R&D investment of ¥199.4 billion for 2011/12,* Astellas aims to strengthen its capabilities as a research-driven pharmaceutical company, playing the vital role of bringing innovative therapies within reach of patients around the world and continuing to build trusted networks amongst physicians and partners.
* Based on figures year ending March 2011.